Journal article
Research priorities in epilepsy for the Asia-Oceanian region
Patrick Kwan, Leonor Cabral-Lim, Wendyl D'Souza, Satish Jain, Byung-In Lee, Weiping Liao, Shih-Hui Lim, Taisuke Otsuki, Chong-Tin Tan, Masako Wantanabe
Epilepsia | WILEY | Published : 2015
DOI: 10.1111/epi.12957
Abstract
The Asia-Oceanian region is the most populous region in the world. Although there has been substantial economic development and improvement in health services in recent years, epilepsy remains generally an underrecognized and understudied condition. To help promote research in the region, the Commission on Asian and Oceanian Affairs (CAOA) of the International League Against Epilepsy (ILAE) appointed the Research Task Force (RTF) to facilitate the development of research priorities for the region. Research that focuses on issues that are unique or of particular importance in the Asia-Oceanian region is encouraged, and that captures the impact of the dynamic socioeconomic changes taking place..
View full abstractGrants
Funding Acknowledgements
This report was written by experts selected by the International League Against Epilepsy (ILAE) and was approved for publication by the ILAE. Opinions expressed by the authors, however, do not necessarily represent the policy or position of the ILAE. P. Kwan has received honoraria for speaking from Eisai, GlaxoSmithKline, and UCB Pharma, and has served on scientific advisory boards for Eisai and GlaxoSmithKline; his institution has received research funding from Eisai, GlaxoSmithKline, and UCB Pharma. W. D'Souza has received travel, investigator-initiated, speaker honoraria and has served on scientific advisory boards from UCB Pharma; educational grants from Novartis Pharmaceuticals, Pfizer Pharmaceuticals, and Sanofi-Synthelabo; educational, travel, and fellowship grants from GlaxoSmithKline Neurology Australia, has served on scientific advisory boards and received honoraria from SciGen Pharmaceuticals. His institute has received research funding from GlaxoSmithKline, SciGen, Pfizer, Novartis, and UCB Pharma. All the other authors have no conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.